



(51) International Patent Classification:
C07K 16/12 (2006.01) A61P 31/04 (2006.01)

(21) International Application Number:
PCT/EP2024/068217

(22) International Filing Date:
27 June 2024 (27.06.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
23182149.7 28 June 2023 (28.06.2023) EP

(71) Applicant: UNIVERSITÄT ZU KÖLN [DE/DE]; Alber-
tus-Magnus-Platz, 50923 Köln (DE).

(72) Inventors: KLEIN, Florian; Erkelenzer Str. 8, 50933 Köln
(DE). RYBNIKER, Jan; Stülzburgstr. 115, 50937 Köln
(DE). SIMONIS, Alexander; Virchowstr.12, 50935 Köln
(DE). KREER, Christoph; Clara-Schumann-Straße 10,
50129 Bergheim (DE).


(74) Agent: KLÖCKNER, Christoph; df-mp Dörries Frank-
Molnia & Pohlman Patentanwälte Rechtsanwälte PartG
mbB, Theatinerstraße 16, 80333 Munich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AGAINST P. AERUGINOSA

Fig. 1



(57) Abstract: The present disclosure relates to antibodies or antigen-binding fragments thereof against Pseudomonas aeruginosa, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, kits comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof, the pharmaceutical compositions and the kits for use as a medicament, and in the treatment or prevention of a disease caused by Pseudomonas aeruginosa. The present disclosure further relates to methods of treating, preventing or reducing the severity of an infection with Pseudomonas aeruginosa, and to nucleic acids encoding such antibodies or antigen-binding fragments thereof, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for the production of such antibodies or antigen-binding fragments thereof.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*